JP2005508916A - 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 - Google Patents

霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 Download PDF

Info

Publication number
JP2005508916A
JP2005508916A JP2003531968A JP2003531968A JP2005508916A JP 2005508916 A JP2005508916 A JP 2005508916A JP 2003531968 A JP2003531968 A JP 2003531968A JP 2003531968 A JP2003531968 A JP 2003531968A JP 2005508916 A JP2005508916 A JP 2005508916A
Authority
JP
Japan
Prior art keywords
domain
composition
glycoprotein
ebola
defective adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003531968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508916A5 (enExample
Inventor
ジェイ． ネイベル，ガリー
ヤン，ジ−ヨン
サリバン，ナンシー
サンチェス，アンソニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2005508916A publication Critical patent/JP2005508916A/ja
Publication of JP2005508916A5 publication Critical patent/JP2005508916A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2003531968A 2001-10-01 2002-09-24 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 Pending JP2005508916A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32647601P 2001-10-01 2001-10-01
PCT/US2002/030251 WO2003028632A2 (en) 2001-10-01 2002-09-24 Development of a preventive vaccine for filovirus infection in primates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005280131A Division JP4198148B2 (ja) 2001-10-01 2005-09-27 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発

Publications (2)

Publication Number Publication Date
JP2005508916A true JP2005508916A (ja) 2005-04-07
JP2005508916A5 JP2005508916A5 (enExample) 2006-10-12

Family

ID=23272371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003531968A Pending JP2005508916A (ja) 2001-10-01 2002-09-24 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発
JP2005280131A Expired - Lifetime JP4198148B2 (ja) 2001-10-01 2005-09-27 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005280131A Expired - Lifetime JP4198148B2 (ja) 2001-10-01 2005-09-27 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発

Country Status (9)

Country Link
US (5) US7635688B2 (enExample)
EP (1) EP1504112A4 (enExample)
JP (2) JP2005508916A (enExample)
AT (1) ATE396739T1 (enExample)
AU (1) AU2002327049B2 (enExample)
CA (4) CA2776522C (enExample)
DE (1) DE60226911D1 (enExample)
ES (1) ES2307093T3 (enExample)
WO (1) WO2003028632A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503206A (ja) * 2010-12-14 2014-02-13 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシズ アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2015527297A (ja) * 2012-04-12 2015-09-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
KR20170048396A (ko) * 2014-09-03 2017-05-08 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
JP2018505185A (ja) * 2015-01-28 2018-02-22 インテグレイテッド バイオセラピューティクス，インコーポレイテッド ウマ免疫グロブリン組成物及びフィロウイルス媒介疾患の治療のための使用

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654370B1 (en) * 2003-08-01 2018-05-30 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Accelerated ebola vaccination
EP1675613B1 (en) * 2003-09-15 2012-05-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Hiv vaccines based on env of multiple clades of hiv
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
EP1737885A2 (en) * 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
AU2005274948B2 (en) * 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
CA2581840C (en) 2004-09-27 2014-08-05 Crucell Holland B.V. Optimized vaccines to provide protection against ebola and other viruses
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
CA2642644A1 (en) * 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
EP2152889B1 (en) 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
WO2009092038A1 (en) * 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
AU2009259456A1 (en) 2008-06-20 2009-12-23 Basf Se Agrochemical formulations comprising a pesticide, an organic UV-photoprotective filter and coated metal-oxide nanoparticles
EP3351628B1 (en) 2008-10-24 2023-07-26 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
CN102317308A (zh) 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
US9125411B2 (en) 2010-04-15 2015-09-08 Basf Se UV absorbers for reducing the E/Z isomerization of pesticides
WO2011130627A2 (en) 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012170814A1 (en) * 2011-06-08 2012-12-13 The Ohio State University Norovirus immunogens and related materials and methods
ES2758713T3 (es) * 2011-07-11 2020-05-06 Inovio Pharmaceuticals Inc Vacuna de ADN contra el virus de Lassa
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN105792842B (zh) 2013-10-11 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 埃巴病毒疫苗
TWI516602B (zh) 2013-10-29 2016-01-11 臺北醫學大學 高通量篩選高表現細胞之方法及由其篩選之細胞
CN114014937A (zh) 2014-05-27 2022-02-08 美利坚合众国, 由健康及人类服务部部长代表 稳定化的流感血凝素茎区三聚体及其用途
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
TN2018000187A1 (en) 2015-12-04 2019-10-04 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
IL265121B2 (en) 2016-09-02 2023-11-01 Us Health Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2019028266A1 (en) 2017-08-02 2019-02-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services HEPATITIS B NANOPARTICLE VACCINE FOR INFLUENZA VIRUS
CA3100070A1 (en) * 2018-05-18 2019-11-21 Universite Laval Vectors for dna vaccination
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
WO2024138204A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized pfs48/45 proteins and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171596B1 (en) 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6200959B1 (en) 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection
WO2001016183A1 (en) 1999-08-30 2001-03-08 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048207A (ja) * 2010-12-14 2017-03-09 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシズＴＨＥ ＧＯＶＥＲＭＥＮＴ ＯＦ ＴＨＥ ＵＮＩＴＥＤ ＳＴＡＴＥＳ ＯＦ ＡＭＥＲＩＣＡ ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ＴＨＥ ＳＥＣＲＥＴＡＲＹ ＯＦ ＴＨＥ ＤＥＰＡＲＴＭＥＮＴ ＯＦ ＨＥＡＬＴＨ ＡＮＤ ＨＵＭＡＮ ＳＥＲＶＩＣＥＳ アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2014503206A (ja) * 2010-12-14 2014-02-13 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシズ アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2022078289A (ja) * 2012-04-12 2022-05-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
US10034930B2 (en) 2012-04-12 2018-07-31 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2019006787A (ja) * 2012-04-12 2019-01-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
US10765733B2 (en) 2012-04-12 2020-09-08 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2021001191A (ja) * 2012-04-12 2021-01-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2015527297A (ja) * 2012-04-12 2015-09-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP7164353B2 (ja) 2012-04-12 2022-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
US11723969B2 (en) 2012-04-12 2023-08-15 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR20170048396A (ko) * 2014-09-03 2017-05-08 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
KR20230134155A (ko) * 2014-09-03 2023-09-20 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
JP2018505185A (ja) * 2015-01-28 2018-02-22 インテグレイテッド バイオセラピューティクス，インコーポレイテッド ウマ免疫グロブリン組成物及びフィロウイルス媒介疾患の治療のための使用

Also Published As

Publication number Publication date
CA2776391A1 (en) 2003-04-10
US7635688B2 (en) 2009-12-22
US20060148087A1 (en) 2006-07-06
CA2776522A1 (en) 2003-04-10
CA2776272A1 (en) 2003-04-10
US20100297171A1 (en) 2010-11-25
WO2003028632A2 (en) 2003-04-10
US20040259825A1 (en) 2004-12-23
JP2006081549A (ja) 2006-03-30
ATE396739T1 (de) 2008-06-15
AU2002327049B2 (en) 2008-04-03
CA2462455C (en) 2012-07-17
WO2003028632A3 (en) 2004-12-02
CA2776391C (en) 2015-03-31
US20100303857A1 (en) 2010-12-02
EP1504112A2 (en) 2005-02-09
DE60226911D1 (de) 2008-07-10
US8124592B2 (en) 2012-02-28
US8106027B2 (en) 2012-01-31
US20100298414A1 (en) 2010-11-25
US8106026B2 (en) 2012-01-31
CA2462455A1 (en) 2003-04-10
CA2776522C (en) 2015-02-17
CA2776272C (en) 2016-05-17
ES2307093T3 (es) 2008-11-16
JP4198148B2 (ja) 2008-12-17
US7094598B2 (en) 2006-08-22
EP1504112A4 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
JP4198148B2 (ja) 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発
AU2002327049A1 (en) Development of a preventive vaccine for filovirus infection in primates
WO2003028632A9 (en) Development of a preventive vaccine for filovirus infection in primates
US11913013B2 (en) Chimpanzee adenoviral vector-based filovirus vaccines
KR101879892B1 (ko) 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신
CA2581840C (en) Optimized vaccines to provide protection against ebola and other viruses
CN117887735A (zh) 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法
EP1586331B1 (en) Development of a preventive vaccine for filovirus infection in primates
CA2519282C (en) Development of a preventive vaccine for filovirus infection in primates
AU2005244541B2 (en) Development of a preventative vaccine for filovirus infection in primates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050926

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090421